An inhaled drug for the treatment of Parkinson’s disease has shown positive results in a Phase I clinical trial, US-based Civitas Therapeutics has announced.
The study showed that CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations, is safe and easily absorbed into the bloodstream, via the lungs, at levels that are likely to produce a therapeutic outcome.
Go deeper with GlobalData
Civitas plans to present comprehensive data from the Phase I study at a future scientific meeting.
Civitas co-founder and chief medical officer Martin Freed said that due to the unpredictability of oral L-dopa, the therapeutic rationale for using inhaled L-dopa to manage motor fluctuations in Parkinson’s disease was intuitive but, until now, technically impractical.
"The Phase I data demonstrated the transformative potential of CVT-301 to enable patients to better manage their motor symptoms in light of the extensive clinical experience correlating L-dopa plasma levels to symptomatic relief documented over the past 40 years," said Freed.
Civitas chief scientific officer Dr Richard Batycky added, "As expected, the tolerability of CVT-301 and L-dopa pharmacokinetic profile behaved consistently with the other molecules we have taken into the clinic over the last decade.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Our technology’s proven unique ability to deliver a large, precise dose with an immediate onset should enable Parkinson’s patients to abort ‘off’ episodes and thereby helping to avoid debilitating disruptions in their lives," he said.
Image caption: CVT-301 is able to be absorbed into the bloodstream via the lungs ( Image by Renjith Krishnan).
